Cargando…

7.0T nuclear magnetic resonance evaluation of the amyloid beta (1–40) animal model of Alzheimer's disease: comparison of cytology verification

3.0T magnetic resonance spectroscopic imaging is a commonly used method in the research of brain function in Alzheimer's disease. However, the role of 7.0T high-field magnetic resonance spectroscopic imaging in brain function of Alzheimer's disease remains unclear. In this study, 7.0T magn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lei, Dong, Shuai, Zhao, Guixiang, Ma, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Research and Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146198/ https://www.ncbi.nlm.nih.gov/pubmed/25206831 http://dx.doi.org/10.4103/1673-5374.128255

Ejemplares similares

Nuclear disarmament verification via resonant phenomena
por: Hecla, Jake J., et al.
Publicado: (2018)

Animal Models of Alzheimer’s Disease: Utilization of Transgenic Alzheimer’s Disease Models in Studies of Amyloid Beta Clearance
por: Malm, Tarja, et al.
Publicado: (2012)

A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease
por: Van der Auwera, Ingrid, et al.
Publicado: (2005)

Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
por: Marr, Robert A., et al.
Publicado: (2014)

Verbenalin Reduces Amyloid-Beta Peptide Generation in Cellular and Animal Models of Alzheimer’s Disease
por: Lim, Juhee, et al.
Publicado: (2022)

Amyloid Beta in Aging and Alzheimer’s Disease
por: Sehar, Ujala, et al.
Publicado: (2022)

Amyloid-beta Alzheimer targets — protein processing, lipid rafts, and amyloid-beta pores
por: Arbor, Sage C., et al.
Publicado: (2016)

Editorial on, “Amyloid-beta clearance in Alzheimer's disease”
por: Marr, Robert A.
Publicado: (2014)

Amyloid Beta and MicroRNAs in Alzheimer’s Disease
por: Amakiri, Nnana, et al.
Publicado: (2019)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Increased variability in reaction time is associated with amyloid beta pathology at age 70
por: Lu, Kirsty, et al.
Publicado: (2020)

On the Subjective Acceptance during Cardiovascular Magnetic Resonance Imaging at 7.0 Tesla
por: Klix, Sabrina, et al.
Publicado: (2015)

On the subjective acceptance during cardiovascular magnetic resonance imaging at 7.0 Tesla
por: Klix, Sabrina, et al.
Publicado: (2015)

Neuroinflammation and amyloid-beta 40 are associated with reduced serotonin transporter (SERT) activity in a transgenic model of familial Alzheimer’s disease
por: Metaxas, Athanasios, et al.
Publicado: (2019)

The amyloid beta ion channel hypothesis of Alzheimer’s disease
por: Shirwany, Najeeb A, et al.
Publicado: (2007)

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
por: Cheignon, C., et al.
Publicado: (2017)

Impaired hepatic amyloid-beta degradation in Alzheimer’s disease
por: Maarouf, Chera L., et al.
Publicado: (2018)

Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain
por: Wildburger, Norelle C., et al.
Publicado: (2017)

Amyloid-Beta: A Crucial Factor in Alzheimer's Disease
por: Sadigh-Eteghad, Saeed, et al.
Publicado: (2015)

The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer’s Disease
por: Hillen, Heinz
Publicado: (2019)

Natural Products Targeting Amyloid Beta in Alzheimer’s Disease
por: Lee, Joo-Hee, et al.
Publicado: (2021)

Optical Imaging of Beta-Amyloid Plaques in Alzheimer’s Disease
por: Luo, Ziyi, et al.
Publicado: (2021)

Cardiometabolic Modification of Amyloid Beta in Alzheimer’s Disease Pathology
por: Hefner, Marleigh, et al.
Publicado: (2021)

The HSP40 chaperone Ydj1 drives amyloid beta 42 toxicity
por: Ring, Julia, et al.
Publicado: (2022)

Nuclear Magnetic Resonance of Hydrogen Molecules Trapped inside C(70) Fullerene Cages
por: Mamone, Salvatore, et al.
Publicado: (2013)

An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease: pyroglutamate amyloid beta
por: Vukicevic, M., et al.
Publicado: (2022)

High Spatial Resolution Cardiovascular Magnetic Resonance at 7.0 Tesla in Patients with Hypertrophic Cardiomyopathy – First Experiences: Lesson Learned from 7.0 Tesla
por: Prothmann, Marcel, et al.
Publicado: (2016)

The role of animal models in advancing amyloid-beta immunotherapy to the clinic
por: Games, Dora, et al.
Publicado: (2010)

Human antibodies reactive with beta-amyloid protein in Alzheimer's disease
Publicado: (1993)

Cessation of Neoangiogenesis in Alzheimer's Disease Follows Amyloid-beta Immunization
por: Biron, Kaan E., et al.
Publicado: (2013)

Investigating the effects of beta-amyloid on hippocampal signalling in Alzheimer's disease
por: Warburton, Julia M, et al.
Publicado: (2015)

Moving Away from Amyloid Beta to Move on in Alzheimer Research
por: Moreno-Treviño, María G., et al.
Publicado: (2015)

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
por: Moro, Maria Luisa, et al.
Publicado: (2018)

Simvastatin Efficiently Reduces Levels of Alzheimer’s Amyloid Beta in Yeast
por: Dhakal, Sudip, et al.
Publicado: (2019)

Protective Factors Modulate the Risk of Beta Amyloid in Alzheimer's Disease
por: Zhou, Bin, et al.
Publicado: (2020)

The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
por: Yin, Xiaomin, et al.
Publicado: (2021)

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
por: Roda, Alejandro R., et al.
Publicado: (2022)

Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
por: Hillen, Heinz
Publicado: (2023)

TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer’s Disease
por: La Rosa, Francesca, et al.
Publicado: (2023)

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
por: Xiaoguang, Wu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_up2pir6elfc6i6m4bilt3de8ci